Variables |  | Total | low ΔPNI | high ΔPNI |  |
---|---|---|---|---|---|
 |  | n = 191 (%) | n = 91 (%) | n = 100 (%) | p value |
Age(mean ± SD) |  | 51.2 ± 10.4 | 50.9 ± 9.26 | 51.5 ± 11.3 | 0.68 |
Sex(Male/Female) | Â | 0/191 | 0/91 | 0/100 | Â |
Pre-NAC clinical stage | I | 1 (0.5%) | 1 (1.1%) | 0 (0%) | 0.67 |
 | II | 118 (61.8%) | 52 (57.2%) | 66 (66.0%) |  |
 | III | 72 (37.7%) | 38 (41.7%) | 34 (34.0%) |  |
 | IV | 0 (0%) | 0 (0%) | 0 (0%) |  |
Histological type | IDC | 171 (89.5%) | 81 (89.0%) | 90 (90.0%) | 0.89 |
 | ILC | 12 (6.3%) | 7 (7.7%) | 5 (5.0%) |  |
 | Special type | 8 (4.2%) | 3 (3.3%) | 5 (5.0%) |  |
HG | 1 | 54 (28.3%) | 18 (19.9%) | 36 (36.0%) | 0.15 |
 | 2 | 89 (46.6%) | 47 (51.6%) | 42 (42.0%) |  |
 | 3 | 23 (12.0%) | 14 (15.3%) | 9 (9.0%) |  |
 | Unknown | 25 (13.1%) | 12 (13.2%) | 13 (13.0%) |  |
Subtype | Lunimal | 107 (56.0%) | 51 (56.0%) | 56 (56.0%) | 0.79 |
 | Luninal HER2 | 37 (19.4%) | 19 (20.9%) | 18 (18.0%) |  |
 | HER2 enriched | 24 (12.6%) | 12 (13.2%) | 12 (12.0%) |  |
 | TNBC | 23 (12.0%) | 9 (9.9%) | 14 (14.0%) |  |
Regimens of NAC | AC | 11 (5.8%) | 10 (11.0%) | 1 (1.0%) | 0.02 |
 | AC → PTX and/or HER | 91 (47.6%) | 52 (57.2%) | 39 (39.0%) |  |
 | AC → DOC and/or HER | 89 (46.6%) | 29 (31.8%) | 60 (60.0%) |  |
Operation procedures | Bt,Ax | 128 (67.1%) | 59 (64.8%) | 69 (69.0%) | 0.65 |
 | Bp,Ax | 63 (32.9%) | 32 (35.2%) | 31 (31.0%) |  |
Pathological response to NAC | non-pCR | 154 (80.6%) | 78 (85.7%) | 76 (76.0%) | 0.10 |
 | pCR | 37 (19.4%) | 13 (14.3%) | 24 (24.0%) |  |
Pre-NAC PNI |  | 52.6 ± 3.8 | 50.9 ± 3.7 | 54.1 ± 3.6 | < 0.01 |
Post-NAC PNI |  | 46.5 ± 4.5 | 48.8 ± 3.9 | 44.5 ± 4.0 | < 0.01 |
Recurrence | Â | 38 (19.9%) | 13 (14.3%) | 25 (25.0%) | 0.06 |